Pharmafile Logo

Vaccine hesitancy eBook

June 7, 2021 | #COVID19, coronavirus, vaccines 

In this e-book, we answer the difficult questions around vaccine hesitancy. Our consultants and commercial experts explore the behavioural science and reveal strategies for improving uptake.

- PMLiVEToday, all eyes are on vaccines. At its high, the US administered 3.4 million doses of the COVID-19 vaccines per day, but in April, this number dwindled to 2.2 million per day. The vulnerable and those who passionately support the vaccines had queued up to become the first to be immunized, sometimes driving hours to get their shot.

However, now that the most enthusiastic populations have been vaccinated, life science companies, healthcare professionals, and the government are up against the challenging task of coaxing the 31% of Americans who are vaccine-hesitant into signing up for the vaccine.

States, corporations, and vaccination centers are even offering incentives from doughnuts and free beer, to savings bonds and marijuana to stimulate demand for vaccines.

In this downloadable pack, we interview industry-leading stakeholders and provide expert analysis from our consultants and commercial experts. Download the PDF to explore:

  • Original research findings on the deeper drivers behind vaccine hesitancy and the benefits of taking a human-centred approach for increasing vaccine uptake
  • The current landscape, expert analysis, and advice for improving vaccine uptake
  • The motivations behind the Arm in Arm campaign, a global campaign designed to encourage donations to ensure everyone across the globe has access to a lifesaving COVID-19 vaccine
  • The social and political drivers fuelling the anti-vax movement
  • The differences between the US and UK immunization programs
  • Why our consultants are volunteering to be part of the UK immunization program

DOWNLOAD THE EBOOK HERE

This content was provided by Avalere Health

Company Details

 Latest Content from  Avalere Health 

5 ways we’re enhancing our services to support our clients in 2023

Fishawack Health CEO Jon Koch explains the new platforms, tools, and services we’re elevating to drive innovation for our clients in 2023.

Why it’s time to apply a payer lens to your early pipeline planning

Value, evidence, and market access experts Jan McKendrick and Andrea Hamlin reveal why applying a payer lens early in the value assessment of pipeline assets is essential for driving commercial...

The fast-paced future of cell and gene therapies

In this report, we interview patients, researchers, and biopharmaceutical leaders to explore the complex landscape for the development of cell and gene therapies and share commercial recommendations from our specialist...

Omnichannel scientific engagement and the use of archetypes to drive personalization

Natasha Cowan, Senior Corporate Communications Manager, explores with Gary Lyons, Head of Strategy, his recent plenary session at the 18th Annual ISMPP conference that focused on how scientific communicators can...

The promised land of gene therapy: Commercialization of novel gene-editing technology in beta-thalassemia

With transformative treatments that leverage CRISPR technology, there are many challenges to overcome throughout the journey of development through to patient access. We interviewed a researcher at a top 20...

Report: Reinventing product and portfolio value for the biopharmaceutical industry

Gain practical advice on determining and communicating product and portfolio value, including why, in fast-paced and evolving markets, you need to consider the evidence requirements of a growing network of...

Practical advice for Early Scientific Advice (ESA) in HTA submissions

A step-by step guide on the benefits, processes, and key considerations involved in the Healthcare Technology Assessment (HTA) Early Scientific Advice (ESA) consultation as part of planning the holistic evidence...

Geoff Thorne joins FH as Chief Technology Officer to drive innovation for clients

The experienced executive will expand our cross-functional omnichannel, data and analytics, and technology offerings, developing effective solutions to meet our clients’ evolving needs.

Shaping the dermatology landscape: Independent expert analysis of the pipeline in 5 disease areas

Leading dermatologists discuss the innovations shaping 5 chronic skin diseases—psoriasis, atopic dermatitis, alopecia areata, vitiligo, and hidradenitis suppurativa—and share the challenges and opportunities for biopharmaceutical companies developing innovative treatments.

How the WHO hepatitis strategy measures up in the field

With hepatitis cases on the rise, Dr Anthony Martinez, member of the International Hepatitis Education Program (IHEP), shares his perspective on the World Health Organization’s new strategy for hepatitis elimination...